Ginkgo biloba extract ameliorates skin fibrosis in a bleomycin-induced mouse model of systemic sclerosis

Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by skin and internal organ fibrosis and obliterative vasculopathy. Few effective treatments are currently available for fibrosis in SSc, therefore, demand persists for novel therapies. Although use of Ginkgo biloba extract (GBE)...

Full description

Saved in:
Bibliographic Details
Main Authors: Beomgu Lee, Jong Seong Roh, Hoim Jeong, Yerin Kim, Jihyeon Lee, Changun Yun, Jiyoung Park, Da-sol Kim, Jungsoo Lee, Min Wook So, Aran Kim, Dong Hyun Sohn, Seung-Geun Lee
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Animal Cells and Systems
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19768354.2024.2337761
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by skin and internal organ fibrosis and obliterative vasculopathy. Few effective treatments are currently available for fibrosis in SSc, therefore, demand persists for novel therapies. Although use of Ginkgo biloba extract (GBE) has been reported to improve blood circulation and alleviate liver and lung fibrosis, its effect on skin fibrosis in SSc remains unclear. In this study, the effects and underlying mechanisms of GBE on skin fibrosis in bleomycin (BLM)-induced mouse model of SSc was investigated. GBE significantly reduced dermal thickness and protein levels of profibrotic factors in the BLM-induced SSc mouse model. Moreover, GBE inhibited the gene expression of profibrotic factors, such as COL1A1, α-SMA, and connective tissue growth factor (CTGF), in fibroblasts by suppressing transforming growth factor (TGF)-β signaling. Furthermore, GBE inhibited the transdifferentiation of adipocytes into myofibroblasts. Thus, our findings suggest that GBE is a promising therapeutic candidate for the treatment of SSc.
ISSN:1976-8354
2151-2485